PH26214A - Pharmaceutical formulation for the treatment of bacterial infections - Google Patents
Pharmaceutical formulation for the treatment of bacterial infections Download PDFInfo
- Publication number
- PH26214A PH26214A PH35336A PH35336A PH26214A PH 26214 A PH26214 A PH 26214A PH 35336 A PH35336 A PH 35336A PH 35336 A PH35336 A PH 35336A PH 26214 A PH26214 A PH 26214A
- Authority
- PH
- Philippines
- Prior art keywords
- coli
- fic
- strain
- citrobacter freundii
- values
- Prior art date
Links
- 208000035143 Bacterial infection Diseases 0.000 title description 5
- 208000022362 bacterial infectious disease Diseases 0.000 title description 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000002195 synergetic effect Effects 0.000 claims description 131
- 239000000203 mixture Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 8
- 238000009472 formulation Methods 0.000 claims description 7
- 150000002148 esters Chemical class 0.000 claims description 6
- 230000000694 effects Effects 0.000 claims description 5
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000001580 bacterial effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 241000588724 Escherichia coli Species 0.000 description 249
- 241000588919 Citrobacter freundii Species 0.000 description 125
- 239000000654 additive Substances 0.000 description 66
- 238000000034 method Methods 0.000 description 66
- 230000000996 additive effect Effects 0.000 description 65
- 230000002401 inhibitory effect Effects 0.000 description 65
- 230000003993 interaction Effects 0.000 description 64
- 239000011734 sodium Substances 0.000 description 51
- 229910052708 sodium Inorganic materials 0.000 description 50
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 49
- GPRBEKHLDVQUJE-VINNURBNSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-VINNURBNSA-N 0.000 description 30
- VAAUVRVFOQPIGI-SPQHTLEESA-N ceftriaxone Chemical compound S([C@@H]1[C@@H](C(N1C=1C(O)=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C(=O)NN1C VAAUVRVFOQPIGI-SPQHTLEESA-N 0.000 description 26
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 24
- GCFBRXLSHGKWDP-XCGNWRKASA-N cefoperazone Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC(O)=CC=1)C(=O)N[C@@H]1C(=O)N2C(C(O)=O)=C(CSC=3N(N=NN=3)C)CS[C@@H]21 GCFBRXLSHGKWDP-XCGNWRKASA-N 0.000 description 23
- DKOQGJHPHLTOJR-WHRDSVKCSA-N cefpirome Chemical compound N([C@@H]1C(N2C(=C(C[N+]=3C=4CCCC=4C=CC=3)CS[C@@H]21)C([O-])=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 DKOQGJHPHLTOJR-WHRDSVKCSA-N 0.000 description 23
- -1 methoxy, vinyl Chemical group 0.000 description 20
- HHXMXAQDOUCLDN-RXMQYKEDSA-N penem Chemical compound S1C=CN2C(=O)C[C@H]21 HHXMXAQDOUCLDN-RXMQYKEDSA-N 0.000 description 15
- 159000000000 sodium salts Chemical class 0.000 description 14
- 229940124587 cephalosporin Drugs 0.000 description 13
- 229910052700 potassium Inorganic materials 0.000 description 13
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 12
- 229960001242 cefotiam Drugs 0.000 description 12
- 239000000306 component Substances 0.000 description 12
- 239000011591 potassium Substances 0.000 description 12
- 229930186147 Cephalosporin Natural products 0.000 description 11
- 229960000466 cefpirome Drugs 0.000 description 11
- 150000001780 cephalosporins Chemical class 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- DMJNNHOOLUXYBV-PQTSNVLCSA-N meropenem Chemical compound C=1([C@H](C)[C@@H]2[C@H](C(N2C=1C(O)=O)=O)[C@H](O)C)S[C@@H]1CN[C@H](C(=O)N(C)C)C1 DMJNNHOOLUXYBV-PQTSNVLCSA-N 0.000 description 8
- 244000052769 pathogen Species 0.000 description 8
- 229910052739 hydrogen Inorganic materials 0.000 description 7
- 239000001257 hydrogen Substances 0.000 description 7
- MVTIDDWEBUVRRW-XIDCRBKBSA-N (5r,6s)-3-(4-carbamoylphenoxy)-6-[(1r)-1-hydroxyethyl]-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid Chemical compound S([C@@H]1[C@H](C(N1C=1C(O)=O)=O)[C@H](O)C)C=1OC1=CC=C(C(N)=O)C=C1 MVTIDDWEBUVRRW-XIDCRBKBSA-N 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 6
- 150000001768 cations Chemical class 0.000 description 6
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- FYZUENZXIZCLAZ-UHFFFAOYSA-N 2-methylhept-2-enoic acid Chemical compound CCCCC=C(C)C(O)=O FYZUENZXIZCLAZ-UHFFFAOYSA-N 0.000 description 4
- 241000606124 Bacteroides fragilis Species 0.000 description 4
- 230000003115 biocidal effect Effects 0.000 description 4
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 206010013710 Drug interaction Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007942 carboxylates Chemical class 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 2
- 229940000425 combination drug Drugs 0.000 description 2
- 239000013066 combination product Substances 0.000 description 2
- 229940127555 combination product Drugs 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 150000002961 penems Chemical class 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OTTZHAVKAVGASB-UHFFFAOYSA-N 2-heptene Natural products CCCCC=CC OTTZHAVKAVGASB-UHFFFAOYSA-N 0.000 description 1
- 241001135228 Bacteroides ovatus Species 0.000 description 1
- 241000606123 Bacteroides thetaiotaomicron Species 0.000 description 1
- 241000606215 Bacteroides vulgatus Species 0.000 description 1
- 101100459774 Caenorhabditis elegans nas-12 gene Proteins 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 241001503991 Consolida Species 0.000 description 1
- 241001137251 Corvidae Species 0.000 description 1
- 101100186820 Drosophila melanogaster sicily gene Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000606210 Parabacteroides distasonis Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- OKBVVJOGVLARMR-QSWIMTSFSA-N cefixime Chemical compound S1C(N)=NC(C(=N\OCC(O)=O)\C(=O)N[C@@H]2C(N3C(=C(C=C)CS[C@@H]32)C(O)=O)=O)=C1 OKBVVJOGVLARMR-QSWIMTSFSA-N 0.000 description 1
- 229960002129 cefixime Drugs 0.000 description 1
- GPRBEKHLDVQUJE-QSWIMTSFSA-N cefotaxime Chemical compound N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CSC(N)=N1 GPRBEKHLDVQUJE-QSWIMTSFSA-N 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 244000000058 gram-negative pathogen Species 0.000 description 1
- 244000000059 gram-positive pathogen Species 0.000 description 1
- LJKNRSBEKUSSIE-UHFFFAOYSA-N hept-2-ene Chemical compound [CH2]CCCC=CC LJKNRSBEKUSSIE-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000015108 pies Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- AZZMGZXNTDTSME-AAUIGXPGSA-M sodium;(6r,7r)-3-(acetyloxymethyl)-7-[[(2e)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyiminoacetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate Chemical compound [Na+].N([C@@H]1C(N2C(=C(COC(C)=O)CS[C@@H]21)C([O-])=O)=O)C(=O)/C(=N/OC)C1=CSC(N)=N1 AZZMGZXNTDTSME-AAUIGXPGSA-M 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
- A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Cephalosporin Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19863618813 DE3618813A1 (de) | 1986-06-04 | 1986-06-04 | Pharmazeutische zubereitung zur behandlung bakterieller infektionen |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH26214A true PH26214A (en) | 1992-03-18 |
Family
ID=6302277
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH35336A PH26214A (en) | 1986-06-04 | 1987-06-02 | Pharmaceutical formulation for the treatment of bacterial infections |
Country Status (27)
| Country | Link |
|---|---|
| US (1) | US4919932A (pt) |
| EP (1) | EP0248361B1 (pt) |
| JP (1) | JPS62292721A (pt) |
| CN (1) | CN87104023A (pt) |
| AR (1) | AR241305A1 (pt) |
| AT (1) | ATE71299T1 (pt) |
| AU (1) | AU597068B2 (pt) |
| CA (1) | CA1294217C (pt) |
| DD (1) | DD257015A5 (pt) |
| DE (2) | DE3618813A1 (pt) |
| DK (1) | DK166759B1 (pt) |
| EG (1) | EG18213A (pt) |
| ES (1) | ES2035829T3 (pt) |
| FI (1) | FI872459A (pt) |
| GR (1) | GR3003856T3 (pt) |
| HU (1) | HU199288B (pt) |
| IL (1) | IL82767A (pt) |
| MA (1) | MA20994A1 (pt) |
| MY (1) | MY101079A (pt) |
| NO (1) | NO872331L (pt) |
| NZ (1) | NZ220509A (pt) |
| OA (1) | OA08609A (pt) |
| PH (1) | PH26214A (pt) |
| PL (1) | PL266058A1 (pt) |
| PT (1) | PT84996B (pt) |
| TN (1) | TNSN87077A1 (pt) |
| ZA (1) | ZA873970B (pt) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1231487B (it) * | 1988-10-24 | 1991-12-07 | Erba Carlo Spa | Composizione sinergica antibatterica contenente penem e ceftizoximaf |
| DE69019395D1 (de) * | 1989-02-21 | 1995-06-22 | Banyu Pharma Co Ltd | Zusammensetzung gegen Mikroben. |
| DE3909056A1 (de) * | 1989-03-18 | 1990-09-20 | Hoechst Ag | Pharmazeutische kombinationspraeparate und deren verwendung zur prophylaxe oder behandlung bakterieller infektionskrankheiten |
| US7491263B2 (en) * | 2004-04-05 | 2009-02-17 | Technology Innovation, Llc | Storage assembly |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS54126735A (en) * | 1978-03-24 | 1979-10-02 | Toyama Chem Co Ltd | Bactericidal composition for medical use |
| EP0041768B1 (en) * | 1980-04-24 | 1987-11-11 | Beecham Group Plc | Beta-lactam compounds, their preparation and use |
| ES8305366A1 (es) * | 1981-07-08 | 1983-04-01 | Hoechst Uk Ltd | "procedimiento para la preparacion de derivados de penem". |
| EP0120613A1 (en) * | 1983-03-02 | 1984-10-03 | Beecham Group Plc | Penem derivatives and precursors |
| DE3424144A1 (de) * | 1984-06-30 | 1986-01-09 | Bayer Ag, 5090 Leverkusen | Verfahren zur erhoehung der bruchfestigkeit von granalien |
-
1986
- 1986-06-04 DE DE19863618813 patent/DE3618813A1/de not_active Withdrawn
-
1987
- 1987-05-29 DE DE8787107803T patent/DE3775823D1/de not_active Expired - Fee Related
- 1987-05-29 ES ES198787107803T patent/ES2035829T3/es not_active Expired - Lifetime
- 1987-05-29 AT AT87107803T patent/ATE71299T1/de active
- 1987-05-29 EP EP87107803A patent/EP0248361B1/de not_active Expired - Lifetime
- 1987-06-02 AR AR87307752A patent/AR241305A1/es active
- 1987-06-02 MA MA21233A patent/MA20994A1/fr unknown
- 1987-06-02 PH PH35336A patent/PH26214A/en unknown
- 1987-06-02 HU HU872525A patent/HU199288B/hu not_active IP Right Cessation
- 1987-06-02 DD DD87303436A patent/DD257015A5/de not_active IP Right Cessation
- 1987-06-02 MY MYPI87000752A patent/MY101079A/en unknown
- 1987-06-02 NZ NZ220509A patent/NZ220509A/xx unknown
- 1987-06-02 US US07/056,712 patent/US4919932A/en not_active Expired - Fee Related
- 1987-06-02 EG EG452/87A patent/EG18213A/xx active
- 1987-06-02 FI FI872459A patent/FI872459A/fi not_active Application Discontinuation
- 1987-06-03 ZA ZA873970A patent/ZA873970B/xx unknown
- 1987-06-03 CA CA000538710A patent/CA1294217C/en not_active Expired - Fee Related
- 1987-06-03 NO NO872331A patent/NO872331L/no unknown
- 1987-06-03 PL PL1987266058A patent/PL266058A1/xx unknown
- 1987-06-03 PT PT84996A patent/PT84996B/pt unknown
- 1987-06-03 DK DK284787A patent/DK166759B1/da not_active IP Right Cessation
- 1987-06-03 AU AU73795/87A patent/AU597068B2/en not_active Ceased
- 1987-06-04 CN CN198787104023A patent/CN87104023A/zh active Pending
- 1987-06-04 IL IL82767A patent/IL82767A/xx not_active IP Right Cessation
- 1987-06-04 OA OA59134A patent/OA08609A/xx unknown
- 1987-06-04 JP JP62140717A patent/JPS62292721A/ja active Pending
- 1987-06-04 TN TNTNSN87077A patent/TNSN87077A1/fr unknown
-
1992
- 1992-02-20 GR GR920400271T patent/GR3003856T3/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| O'callaghan et al. | GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity | |
| Brumfitt et al. | Cefoxitin and cephalothin: antimicrobial activity, human pharmacokinetics, and toxicology | |
| Viladrich et al. | Evaluation of vancomycin for therapy of adult pneumococcal meningitis | |
| Paisley et al. | Combined activity of clavulanic acid and ticarcillin against ticarcillin-resistant, gram-negative bacilli | |
| Fu et al. | Piperacillin, a new penicillin active against many bacteria resistant to other penicillins | |
| Georgopapadakou et al. | Binding of beta-lactam antibiotics to penicillin-binding proteins of Staphylococcus aureus and Streptococcus faecalis: relation to antibacterial activity | |
| Chin et al. | Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection | |
| Pruul et al. | Potentiation of antibacterial activity of azithromycin and other macrolides by normal human serum | |
| Norrby et al. | Comparative in vitro activity of PD 127,391, a new fluorinated 4-quinolone derivative | |
| Meyers et al. | Antibacterial Activity of Cefamandole III Vitro | |
| Winston et al. | Controlled trials of double beta-lactam therapy with cefoperazone plus piperacillin in febrile granulocytopenic patients | |
| PH26214A (en) | Pharmaceutical formulation for the treatment of bacterial infections | |
| Miller et al. | Cephamycins, a new family of β-lactam antibiotics. III. In vitro studies | |
| Daschner et al. | Pharmacokinetics of vancomycin in serum and tissue of patients undergoing open-heart surgery | |
| Yogev et al. | Intraventricular levels of amikacin after intravenous administration | |
| English et al. | Laboratory evaluation of 3-(5-tetrazolyl) penam, a new semisynthetic beta-lactam antibacterial agent with extended broad-spectrum activity | |
| Moore et al. | 6 beta-Iodopenicillanic acid (UI-38,006), a beta-lactamase inhibitor that extends the antibacterial spectrum of beta-lactam compounds: initial bacteriological characterization | |
| Hyslop et al. | Loracarbef (LY163892) versus cefaclor and norfloxacin in the treatment of uncomplicated pyelonephritis | |
| Wise | Comparative microbiological activity and pharmacokinetics of cefprozil | |
| Sheppard et al. | In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents | |
| Randolph et al. | Comparative bactericidal effect of ceforanide (BL-S 786) and five other cephalosporins in an in vitro pharmacokinetic model | |
| Lode et al. | Prospective randomized clinical trials of new quinolones versus b-lactam antibiotics in lower respiratory tract infections | |
| Webber et al. | Moxalactam: The first of a new class of β-lactam antibiotics | |
| Ribner et al. | Treatment of serious infections with moxalactam | |
| Jacobson et al. | Clinical and bacteriological evaluation of cefoxitin therapy in children |